COURSES AND SEMINARS
Chair: M. Aapro, CH
The European School of Oncology is delighted that so many experts of lung, colorectal and breast cancer have accepted to be faculty members of the «Gene Profiling in Oncology» course.
The development of specific treatments, with an endocrine or other «target» is revolutionizing cancer treatment. We need to define the disease of the patient more precisely.
Which parameters are of importance for the efficacy of the treatment? What should be asked from new methods? What do they bring today?
Not all answers will come from the discussions at the meeting, but certainly there will be a lively debate!
We look forward to your presence at this course
Matti S. Aapro
European School of Oncology
Via del Bollo, 4
20123 Milan, Italy
Tel: +39 02 8546 4532
Fax: +39 02 8546 4545
GRAND HOTEL PRINCIPE DI PIEMONTE
Piazza Puccini, 1
55049 Viareggio, Italy
Tel: +39 0584 4011
HOW TO REACH THE VENUE
Viareggio is located on the Tuscan coast. The main airports to reach Viareggio are Pisa (20 Km) and Florence (80 km), both of which have regular national and international flight connections.
A limited number of travel grants will be available. Requests for support should be submitted together with the application form by the application deadline. Travel grant will be awarded up to Euro 300,00.
Application for CME recognition will be submitted to the Accreditation Council for Oncology in Europe.
M. Aapro, IMO Clinique de Genolier, FMH Oncologie-Hématologie, Genolier, CH
J. Albanell Mestres, Hospital del Mar, Barcelona, ES
F. André, Institut Gustave Roussy, Villejuif, FR
O. Gautschi, Luzerner Kantonsspital, Luzern, CH
D. Kerr, University of Oxford, UK
R. Labianca, Ospedali Riuniti di Bergamo, IT
L. Lacroix, Institut Gustave Roussy, Villejuif, FR
T. Le Chevalier, Institut Gustave Roussy, Villejuif, FR
N. Liebermann, Clalit Health Services, Tel Aviv, IL
H. Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US
A. Sobrero, Ospedale San Martino, Genoa, IT
C. Thomssen, Martin-Luther University Halle-Wittenberg, Halle/Saale, DE
G. Viale, European Institute of Oncology, Milan, IT
Introduction: Why has ESO organized this meeting?
WHERE DO WE STAND IN LUNG CANCER?
Treatment of advanced NSCLC: which drugs for which histology? And is histology reliable?
|Do we know how to chose the best maintenance treatment?|
O. Gautschi, CH
New markers to define NSCLC and the potential of genomics
WHERE DO WE STAND IN COLORECTAL CANCER?
What do we do today to chose “targeted agents” in metastatic CRC treatment? Is k-ras mutation enough? What about b-raf? And how to decide between EGFR inhibitions and angiogenesis inhibition?
Is T4 ,fewer than 12 lymph nodes and absence of MMR-D the standard to decide adjuvant chemotherapy in Stage II CRC?
Where are we with genomic testing in CRC? When should we use it?
WHERE DO WE STAND IN BREAST CANCER?
|Classic pathology: why is proliferation difficult to determine? Why is Ki-67 not a standard? What was decided at St. Gallen last week!|
G. Viale, IT
|9:00||Genomic evaluation: what are the data?|
F. André, FR
|9:30||How to integrate the genomic tools in practice|
A panel discussion
|11:00||Why genomic tools in endocrine-responsive tumours: a US perspective|
H. Rugo, US
|11:30||Are genomic tools better than quantitative ER-reporting for determination of benefit of endocrine-therapy? |
C. Thomssen, DE
|12:00||The Spanish experience|
J. Albanell Mestres, ES
But can my health system afford the cost?
Certificates of attendance and Lunch